A Phase 3 interventional study of Phosphate-binder intervention and Phosphorus-restricted dietary intervention in Maintenance Hemodialysis and Hyperphosphatemia, sponsored by Chen Jing. Completed at 2 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-08-31.
Sponsored by Chen Jing · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hyperphosphatemia with a site in China — 5 open to participants now, 6 under way, 1 of them phase 3. Hyperphosphatemia · China.
Among the 18 studies in Hyperphosphatemia with a site in China, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 3, and was the 6th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 15 are open to participants now.
Browse Hyperphosphatemia studies →5 of the 18 studies in Hyperphosphatemia with a site in China are open now. Recruiting first, the newest first:
Alebund Pharmaceuticals · Sites in China, United States
Ages 12+
Jemincare · Sites in China
Ages 18+
Limeng Chen · Sites in China
Huashan Hospital · Sites in China
Peking University People's Hospital · Sites in China
Ages 18–100
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Hyperphosphatemia studies recruiting now, 10 (83%) set no upper age limit and 2 (17%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 7 · Phase 4 1
First in 2011; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 158 across the 15 interventional studies, 200 across the 3 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
Chen Jing is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Chen Jing has 1 study filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Hyperphosphatemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712654R1 TherapeuticsA Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia | 2027-02-28 |
| NCT07776119Peking University People's HospitalReal-World Efficacy and Safety of Tenapanor Plus Phosphate Binders in Hemodialysis Patients With Hyperphosphatemia | 2027-04-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Hyperphosphatemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The research is designed as a prospective, randomized, controlled clinical trial without blinding. A total of 116 participants with hyperphosphatemia will be enrolled from three hemodialysis center (56 from Huashan Hospital, 30 from Huadong Hospital and 30 from Tongji Hospital). All participants will be randomly divided into control group and intervention group in a ratio of 1:1. Phosphorus balance status is evaluated in participants of the intervention group by the phosphorus balance calculator. Then, these participants will be given individualized phosphate-binders, dietary and dialysis intervention according to the results of phosphorus balance evaluation. Participants in the control group will not receive the phosphorus balance status evaluation but receive phosphate-binder treatment according to the KDIGO Guidelines. Dietary phosphorus intake, dialysate calcium concentration and dose of active vitamin D, phosphorus-binders of all participants will be recorded during the whole research program. After two-week treatment, the phosphorus balance of participants in intervention group will be evaluated again and the therapeutic strategies then will be adjusted. At the same time, the therapeutic strategies of participants in the control group will be adjusted according to the serum phosphorus concentration. All participants will be followed up for two weeks again and receive blood test and related examinations at the end of study. The results of final examinations will be analyzed to evaluate the efficacy of individualized treatment of hyperphosphatemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Phosphate-binder intervention
Drug: Phosphate-binder intervention · Dietary Supplement: Phosphorus-restricted dietary intervention
Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
Also known as: Additional dialysis intervention
Serum phosphorus concentration
Time frame: Four weeks after treatment
Achievement rate of serum phosphorus
Time frame: Four weeks after treatment
Serum calcium concentration
Time frame: Four weeks after treatment
Serum iPTH concentration
Time frame: Four weeks after treatment
Serum albumin concentration
Time frame: Four weeks after treatment
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2019 to primary completion in Jan 2021, 13 months.
Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chen Jing